Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.57 |
| ▸ | TUBB | P07437 | 1/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.57 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.57 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.57 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.57 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.57 |
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472829 | 0.85 | TUBB4A (0.78) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10028825 | 0.83 | ADRB2 (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL394853 | 0.82 | ADRB2 (0.56) | LDHAADRB2SLC6A4 | |
| SCHEMBL28615668 | 0.82 | PPARG (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Hypophaol SCHEMBL31529677 | 0.80 | LDHA (0.53) | LDHAALOX15ALOX12CA2STAT3 | |
| Hypophaol SCHEMBL31529678 | 0.80 | LDHA (0.53) | LDHAALOX15ALOX12CA2STAT3 | |
| SCHEMBL4598863 | 0.79 | LDHA (0.64) | LDHAALOX15ALOX12CA2STAT3 | |
| SCHEMBL4598867 | 0.79 | LDHA (0.64) | LDHAALOX15ALOX12CA2STAT3 | |
| SCHEMBL31572667 | 0.79 | LDHA (0.64) | LDHAALOX15ALOX12CA2STAT3 | |
| SCHEMBL29944173 | 0.79 | LDHA (0.64) | LDHAALOX15ALOX12CA2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495436-B | Process for the synthesis of -stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEM | 2014-02-26 | — | — | CN | disclosed |
| EP-2049459-B1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-8101804-B2 | Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2012-01-24 | — | — | US | disclosed |
| EP-2202215-A2 | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | Clariant Specialty Fine Chemicals (France) (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100004483-A1 | Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2049459-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | Clariant Specialty Fine Chemicals (France) (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012321-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004483-A1 | Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol | SQLE, SUCLA2, SORD | TUBB4A 2141/4885TUBB 2918/4885TUBA3C 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.